Skip to main content

Table 2 The overall characteristic information of all patients

From: Multi-omics to predict acute radiation esophagitis in patients with lung cancer treated with intensity-modulated radiation therapy

Characteristics

Overall (161)

ARE (51)

p value

Gender

  

p < 0.001

 Male (N/%)

142/88.2%

47/33.1%

 Female (N/%)

19/11.8%

4/21.1%

Age, median (range)

62 (29–83)

–

p < 0.001

Pathology

  

p < 0.001

 SCC (N/%)

104/64.6%

37/35.6%

 ADC (N/%)

51/31.7%

13/25.5%

 Others (N/%)

6/3.7%

1/16.7%

RT Dose

  

p < 0.001

 Median (range) \(<\) 60 Gy

60 (45–70) Gy

 

 N/%

81/50.3%

24/29.6%

Smoking

  

p < 0.001

 Activity or former (N/%)

123/76.4%

38/30.9%

 Never (N/%)

38/23.6%

13/34.2%

T Stage

  

p < 0.001

 T1 (N/%)

10/6.2%

1/10.0%

 T2 (N/%)

70/43.5%

24/34.3%

 T3 (N/%)

35/21.7%

11/31.4%

 T4 (N/%)

46/28.6%

16/34.8%

N Stage

  

p < 0.001

 N0 (N/%)

9/5.6%

2/22.2%

 N1 (N/%)

4/2.5%

1/25.0%

 N2 (N/%)

85/52.8%

33/38.8%

 N3 (N/%)

63/39.1%

15/23.8%

TNM

  

p < 0.001

 IIIA (N/%)

54/29.2%

20/37.0%

 IIIB (N/%)

107/70.8%

31/29.0%

Treatment technology

  

p < 0.001

 SCRT (N/%)

65/40.4%

17/26.2%

 CCRT (N/%)

87/54.0%

31/35.9%

 RT (N/%)

9/5.6%

3/33.3%

 ARE (N/%)

51/31.7%

–

–

  1. SCC Squamous carcinoma cancer, ADC Adenocarcinoma cancer, SCRT Sequential chemoradiotherapy, CCRT Concurrent chemoradiotherapy